![Alexander Sapir](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alexander Sapir
Chief Executive Officer at
FULCRUM THERAPEUTICS, INC.
Net worth: 719 290 $ as of 2026-07-30
Profile
Mr. Alexander C.
Sapir is a President, Chief Executive Officer & Director at Fulcrum Therapeutics, Inc., an Independent Director at PhaseBio Pharmaceuticals, Inc. and a Chief Executive Officer & Director at ReViral Ltd. He is on the Board of Directors at Fulcrum Therapeutics, Inc., PhaseBio Pharmaceuticals, Inc. and ReViral Ltd. Mr. Sapir was previously employed as a President, Chief Executive Officer & Director by Dova Pharmaceuticals, Inc., an Executive Vice President-Marketing & Sales by United Therapeutics Corp., and a Senior Director-Marketing by Guilford Pharmaceuticals, Inc. He received his undergraduate degree from Franklin & Marshall College and an MBA from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-30 | 200,919 ( 0.26% ) | 719 290 $ | 2026-07-30 |
Alexander Sapir active positions
| Companies | Position | Start |
|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Director/Board Member | 2020-02-11 |
| FULCRUM THERAPEUTICS, INC. | Chief Executive Officer | 2023-06-30 |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Chief Executive Officer | 2019-06-09 |
Former positions of Alexander Sapir
| Companies | Position | End |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Chief Executive Officer | 2018-11-30 |
| UNITED THERAPEUTICS CORPORATION | Sales & Marketing | 2016-04-30 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs used to treat neurological diseases | Sales & Marketing | 2004-12-31 |
Training of Alexander Sapir
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
62
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs used to treat neurological diseases | Health Technology |
United Therapeutics Corp.
 United Therapeutics Corp. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic & life-threatening conditions | Health Technology |
PhaseBio Pharmaceuticals, Inc.
 PhaseBio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapies for cardiovascular diseases | Health Technology |
Franklin & Marshall College
 Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Health Technology |
Fulcrum Therapeutics, Inc.
 Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
- Stock Market
- Insiders
- Alexander Sapir
